Does the ESR1 rs2234693 CT variant alter estrogen receptor activity and estrogen-related bone or metabolic responses?

The ESR1 rs2234693 (PvuII, T>C) polymorphism is a genetic variant in intron 1 of the estrogen receptor alpha (ESR1) gene. Evidence demonstrates that this variant plays a functional role in modulating receptor expression, with downstream, modest effects on bone mineral density (BMD) and metabolic markers.

Molecular mechanisms

• Transcription factor binding: The rs2234693 polymorphism functions as a cis-regulatory, enhancer-like element in intron 1 of the ESR1 gene. The C allele creates a functional binding site for B-Myb and c-Myb transcription factors, which is absent in the T allele.
• Altered receptor expression: In co-transfection reporter gene assays, constructs containing the C allele demonstrate significantly increased downstream gene expression. The heterozygous CT variant corresponds to an intermediate transcriptional profile, resulting in altered expression levels of functional estrogen receptor-alpha.

Bone responses to estrogen signaling

• Intermediate bone density: The heterozygous CT variant is associated with intermediate BMD levels. In multiple cohorts, individuals carrying the TT genotype present with higher BMD relative to CC homozygotes, while CT heterozygotes fall between the two.
• Variable fracture risk: The clinical association of the CT genotype with osteoporosis and fragility fracture risk is modest and highly population-dependent. Some large-scale cohort studies report no significant association, indicating that the genetic effect on bone health is subtle.

Metabolic responses to estrogen signaling

• Lipid profile variations: The rs2234693 genotype is associated with modest variations in lipid profiles. In postmenopausal cohorts, the T allele has been associated with an increased risk of hyperlipidemia.
• Hormone replacement therapy (HRT) response: The variant modulates lipid changes during HRT. Following estrogen therapy, individuals with the TT genotype experience a significantly greater increase in HDL cholesterol, while CT heterozygotes exhibit an intermediate baseline and response profile. These metabolic differences are subtle and are often overshadowed by lifestyle and traditional cardiovascular risk factors.

Bottom line

• The ESR1 rs2234693 CT variant is associated with intermediate estrogen receptor transcriptional activity due to the allele-specific creation of a B-Myb transcription factor binding site. This translates to subtle, intermediate bone density profiles and lipid responses to estrogen signaling, though the clinical manifestations remain highly dependent on population and environmental factors.